ProQR Secures $50M from Eli Lilly After Positive Early Trial Data

Key Facts

1ProQR Therapeutics reported positive Phase 1 data for its drug AX-0810.

2The company raised $50 million in a share offering that included Eli Lilly.

In a move that underscores growing confidence in early-stage biotech, ProQR Therapeutics announced positive Phase 1 data for its drug AX-0810 and concurrently raised $50 million in a share offering that included Eli Lilly. The deal signals large pharma's appetite for promising early-stage assets.

Eli Lilly's investment in ProQR comes as big pharmaceutical companies increasingly seek to diversify their pipelines through strategic partnerships. The capital injection provides ProQR with a solid runway to advance its candidate targeting an undisclosed chronic disease.

Eli Lilly (LLY) shares closed at $1,117.26 on June 24, 2026, trading between $1,100.98 and $1,135.14 during the session. Investors now await further clinical updates for AX-0810 and any regulatory milestones that could affect the stock's trajectory.